How should I discontinue Prolia (denosumab) and what alternative anti‑resorptive therapy should be started to prevent rapid bone loss?

How to Discontinue Prolia (Denosumab)

Do not stop Prolia without immediately starting bisphosphonate therapy—specifically, initiate zoledronate 5 mg IV at 6 months after the last Prolia dose to prevent rebound bone loss and multiple vertebral fractures. 1

Critical Understanding: The Rebound Phenomenon

When you discontinue denosumab, a dangerous rebound occurs within 6-12 months characterized by:

• Rapid increase in bone turnover markers exceeding pre-treatment levels 2
• Accelerated bone loss, often exceeding the gains achieved during treatment 3, 2
• Risk of multiple vertebral fractures in up to 10% of patients without sequential therapy 3, 4
• Increased mortality associated with denosumab delays beyond 7 months or discontinuation without sequential therapy 4

This is not a simple return to baseline—it represents excessive bone resorption that can be catastrophic. 1, 2

Mandatory Sequential Therapy Protocol

Timing and Agent Selection

Start zoledronate (zoledronic acid) 5 mg IV exactly 6-7 months after the last denosumab injection. 1

The ESMO guidelines specifically state: "Discontinuation of denosumab can be associated with vertebral fractures that may be averted if a bisphosphonate is started 6 to 7 months after the last denosumab administration." 1

Alternative Bisphosphonate Options

If zoledronate is contraindicated or unavailable:

• Oral alendronate 70 mg weekly for at least 1 year 1
• Oral risedronate 35 mg weekly for at least 1 year 1
• IV zoledronate 4 mg can be used if the 5 mg dose is not tolerated 1

The optimal regimen remains under investigation, but treatment for at least 1 year with oral bisphosphonates or 1-2 years with IV bisphosphonates is prudent. 1

Risk Stratification for Rebound Fractures

Patients at highest risk for multiple vertebral fractures after denosumab discontinuation include those with: 2

• Pre-existing vertebral fractures (most important risk factor)
• Longer duration of denosumab therapy (>3 years associated with greater rebound)
• Greater gain in hip BMD during denosumab treatment
• Greater loss of hip BMD after stopping therapy

Monitoring Strategy

Bone Turnover Markers

Measure serum CTX (C-terminal telopeptide of type I collagen) at baseline and 3-6 months after starting bisphosphonate therapy to assess adequacy of rebound suppression. 3, 2

Bone Mineral Density

Obtain DXA scan at 12 months after denosumab discontinuation to assess bone loss and guide duration of bisphosphonate therapy. 3, 5

Clinical Vigilance

Maintain heightened awareness for new back pain or height loss during the first 12 months, as most bone loss and fractures occur within this window. 5

Important Caveats and Pitfalls

Prior Bisphosphonate Exposure

Patients with prior bisphosphonate use before denosumab may have partial mitigation of the rebound phenomenon, but this does not eliminate the need for sequential therapy. 2

Duration of Denosumab Treatment Matters

A 2024 randomized trial showed that patients treated with denosumab for ≥3 years experienced significant lumbar spine BMD loss (-3.20%) even with zoledronate sequential therapy, compared to those continuing denosumab. 6 This suggests longer denosumab duration may require more aggressive sequential therapy strategies.

Never Use PTH/PTHrP After Denosumab

Switching from denosumab to teriparatide or abaloparatide leads to transient bone loss at hip and spine and is not recommended. 1 The sequence must be anabolic agent first, then denosumab—never the reverse.

Calcium and Vitamin D

Ensure adequate calcium (1000-1200 mg daily) and vitamin D (1000-2000 IU daily) supplementation throughout the transition period to maintain normal serum calcium and support bone health. 1

Dental Considerations

Complete any necessary invasive dental procedures before starting bisphosphonate therapy, as the risk of osteonecrosis of the jaw continues with bisphosphonates, though at lower rates than with denosumab. 1

Special Populations

Cancer Patients

For patients with cancer-treatment-induced bone loss or bone metastases, the same 6-month timing for bisphosphonate initiation applies, with zoledronate being the preferred agent given existing oncology experience. 1

Glucocorticoid-Induced Osteoporosis

Sequential therapy is strongly recommended after stopping denosumab in patients with glucocorticoid-induced osteoporosis, with bisphosphonate or romosozumab as options, though the optimal formulation and duration remain unclear. 1

When Denosumab Should Continue

Consider long-term denosumab treatment without discontinuation for patients at persistently very high fracture risk (T-score ≤-2.5, history of fragility fracture, or multiple risk factors), given the favorable long-term efficacy and safety profile. 2 The decision to stop should be carefully weighed against the complexity and risks of the transition protocol.